Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Article content
TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6.
Article content
Article content
Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference.
Article content
2025 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Monday, May 5
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre
Article content
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation.
Article content
About Satellos Bioscience Inc.
Article content
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?
If everyone only invested in what they fully understood, I suspect quite a few stocks wouldn't exist today. We can probably put quantum computing stocks in that category. The quantum physics used by companies pioneering quantum computing can make your head spin. Fortunately for many investors, quantum computing stocks do exist. Two of them have been especially big winners -- D-Wave Quantum (NYSE: QBTS) and IonQ (NYSE: IONQ). D-Wave Quantum has delivered the more impressive performance over the last 12 months. Is it a better quantum computing stock than IonQ? The case for D-Wave Quantum Despite the market turbulence experienced in 2025, D-Wave Quantum has generated a staggering return of nearly 1,200% over the last 12 months. Even with this tremendous gain, though, the company's market cap remains below $5 billion. D-Wave's financial performance has been impressive, too. The company's revenue soared 509% year over year in the first quarter of 2025. Its cash position totaled $304.3 million at the end of Q1. D-Wave's management believes that's enough to fund operations until the company achieves profitability. The huge stock gains and strong revenue growth are the result of increasing interest in D-Wave's technology. The company boasts the world's largest quantum computer. D-Wave recently introduced its most advanced system to date, its sixth-generation Advantage2 quantum computer. CEO Alan Baratz said this new system is "so powerful that it can solve hard problems outside the reach of one of the world's largest exascale GPU-based classical supercomputers." D-Wave has completed more than 20 proof-of-concept engagements over the last 18 months. Its customer base includes Deloitte, Fort Otosan (a Turkey-based automaker owned by Ford and Koç Holding), Lockheed Martin, and Japan Tobacco). The case for IonQ IonQ hasn't delivered the kind of gains that D-Wave has over the last 12 months, but it's nonetheless been sizzling hot. The quantum computing pioneer's stock is up roughly 380%. Thanks to this great return, IonQ's market cap now tops $9 billion. At first glance, you might wonder about IonQ's growth. The company's revenue dipped slightly year over year in Q1. However, IonQ's revenue has increased by a compound annual growth rate of 170% since 2021. The company expects that 2025 revenue will nearly double year over year based on the midpoint of its guidance range. IonQ believes that its ion trap architecture gives it distinct competitive advantages. Its quantum computers can operate at room temperature instead of requiring cooling to zero degrees Kelvin. The company thinks its error correction process is superior to rivals. IonQ also maintains that its architecture is more modular and scalable than the competition. All three of the largest cloud platforms offer IonQ's quantum hardware, a claim no other quantum computing company can make. IonQ has a growing customer base that includes big companies such as Ansys, AstraZeneca, and Toyota Tsusho. Better quantum computing stock? Both D-Wave Quantum and IonQ could have tremendous growth potential. Quantum computing could transform many areas, including drug discovery, logistics, and materials science. Consulting firm McKinsey & Co. estimates that quantum computing and networking could create up to $880 billion in economic value by 2040. However, these two companies also face significant risks. Neither D-Wave nor IonQ is profitable yet. Although their respective technological approaches show promise, the competition is intense, with some rivals possessing much greater financial resources. If I had to pick one of these quantum computing stocks right now, I'd go with IonQ. It's generating more revenue than D-Wave. Its intellectual property portfolio is larger, with 950 patents related to quantum computing and networking that should soon be under the company's control. I also like IonQ's business development strategy. Recent acquisitions of ID Quantique and Lightsynq position IonQ well in the quantum networking space. Investing in IonQ isn't for everyone because of the inherent risks with a small company in a fledgling market. However, I think aggressive investors could see market-beating returns from this stock over the long run. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Ansys, AstraZeneca Plc, and Lockheed Martin. The Motley Fool has a disclosure policy.
CTV News
14 hours ago
- CTV News
Olympic and national athletes participate in Canada Life Forest City Road Races
The 2025 Canada Life Forest City Road Races (FCRR) increased its prize money by one-third, and it drew a record crowd with nearly 1,000 more runners over 2024.
Globe and Mail
18 hours ago
- Globe and Mail
Tesla's Downturn Continues as China-Made EV Sales Plunge 15%. Should You Sell TSLA Stock Here?
2025 has been a challenging year for Tesla (TSLA) shareholders, with the stock trading down 25% year-to-date. From CEO Elon Musk's controversial stint in President Donald Trump's administration to collapsing sales in Europe and growing pressure from Chinese competitors like BYD (BYDDY), the headwinds have been relentless. Although Musk's exit from his government role brought momentary relief, the stock hasn't found its footing yet. This was especially evident during this past week, when tensions skyrocketed between President Trump and Musk and it was reported that sales of Tesla's electric vehicles (EVs) in China continued to fall in May and have now fallen for eight straight months. In May alone, deliveries of the Model 3 and Model Y, covering both domestic and export sales, slipped to 61,662 units, marking a 15% year-over-year decline. Even a modest 5.5% rise from April couldn't mask the growing impact of fierce price wars in the world's largest auto market. Meanwhile, BYD, Tesla's top rival, continued to build momentum with a 14.1% year-over-year jump in global passenger vehicle sales, outpacing Tesla even as its own growth cooled from April's 19.4% surge. So, with Tesla under mounting pressure, is it time for investors to hit the brakes and sell? About Tesla Stock Once hailed as the crown jewel of the EV revolution, Tesla (TSLA) is now navigating a stormy 2025. After struggling with Elon Musk's political drama, mounting competition, and falling sales, Tesla is back in the headlines. Just as investors began to relax after Musk stepped away from his role in the Trump administration, fresh drama quickly reignited concerns. This time, it was a very public clash between Musk and Trump over the proposed 'The Big, Beautiful Bill,' a comprehensive piece of legislation currently being debated in the U.S. Congress. Musk heavily criticized this bill on X and Trump fired back by threatening to pull federal contracts and subsidies from both Tesla and SpaceX. The reaction was immediate. On June 5, Tesla shares tanked more than 14%, wiping out a staggering $150 billion in market value in just one day. With Tesla's market cap now hovering around $917 billion, shares of this EV maker are down roughly 30% in 2025, dramatically lagging behind the broader S&P 500 Index's ($SPX) marginal gain during the same stretch. While volatility is nothing new for Tesla investors, its latest sharp drop is evidence of just how tightly the company's fate is tied to Elon Musk's every move. Tesla's Q1 Earnings Snapshot Tesla opened 2025 on a sour note, delivering a first-quarter earnings report on April 22 that fell flat across the board. Revenue dropped 9% year-over-year to $19.3 billion, missing the analysts' target of $21.3 billion. But the real gut punch came from adjusted earnings, which plummeted 40% to just $0.27 per share, coming in nearly 35% below expectations. Tesla's automotive division sputtered in the first quarter, with revenue from its core business plunging 20%, dropping from $17.4 billion to about $14 billion. While the company blamed factory upgrades tied to the Model Y refresh, the damage ran deeper. Steep discounts and falling average selling prices put the brakes on profitability, weighing heavily on both revenue and margins. On a brighter note, Tesla's energy generation business surged 67% year-over-year to $2.7 billion, while its services segment posted a solid 15% gain to $2.6 billion. Still, faced with mounting headwinds across its core operations, Tesla struck a notably cautious tone. Rather than offering bold projections, the company chose to hit pause on big promises, stating it would 'revisit our 2025 guidance in our Q2 update.' What Do Analysts Expect for Tesla Stock? Analysts, much like investors, are starting to tread carefully with TSLA stock. Take Goldman Sachs, for example. The leading investment bank recently trimmed its price target on Tesla from $295 to $285 while sticking with a 'Neutral' rating. The move comes amid signs of slowing momentum, with weaker monthly sales data across major regions like the U.S., Europe, and China. While they're not pulling the plug on Tesla just yet, the tone is clearly more reserved as questions about near-term growth continue to mount. Overall, Wall Street remains on edge, with the consensus firmly favoring a cautious 'Hold' stance amid the ongoing uncertainty. Of the 41 analysts offering recommendations, 16 give it a solid 'Strong Buy,' two suggest a 'Moderate Buy,' 13 advocate 'Hold,' and the remaining 10 give a 'Strong Sell.' The average analyst price target of $292.17, which is actually slightly lower than where the stock is currently trading. However, the Street-high price target for TSLA is $500. Key Takeaways 2025 has been a tumultuous year for Tesla, with the stock significantly underperforming the broader market amid relentless headwinds. Plummeting sales in key markets like China, intense competition from rivals such as BYD, and persistent political drama surrounding CEO Elon Musk – including a recent clash with President Donald Trump – have all contributed to a substantial year-to-date decline and a significant one-day market value loss. Coupled with a disappointing Q1 earnings report, characterized by declining automotive revenue and a cautious outlook, analysts largely maintain a "Hold" rating on TSLA. While the stock's fate remains heavily tied to Musk's actions, and despite some bullish long-term price targets, the near-term outlook for the EV giant is clouded by considerable uncertainty.
